Oh yeah, good news got them nearly to $4.50, and reality bites them back to $3.75 and lower. Pump and dump baby! Could be another TRADING opportunity. Learn the ARRY rhythm method. Drug free.
how long can you keep pumping arry while you collect a huge salary ? and the shares sit at 4.00
You or your cronies wont even spend a penny and buy a share on the open market. Thanks for supporting the share holders
This is from page 3 of the C C:
Given that there are at least 4 million patients with SHPT derived from vitamin D therapy or about 4 million to 4.5 million patients, if we were to price Rayaldee at the lower cost range of vitamin D therapy, which is $3,000 per year, the U.S. CKD market alone represents a potential $12 billion revenue opportunity. Now we are approximately 1.5 years away from launch, so we have plenty of time to sharpen our pricing strategy and to adjust it as necessary. There's plenty of room for adjustment as you can see.
Why is Rayaldee the solution to the unmet need? Rayaldee is a modified-release oral formulation of 25-hydroxyvitamin D3, the prohormone form of vitamin D3. This prohormone is a blood-borne storage form of vitamin D and is monitored by physicians to determine the vitamin D status of their patients.
Well makes you wonder what NVS is seeing [or not seeing]. I exited in 4.40s after the big spike. Like you say - happy trading. Actually hope these prices stay low for a few more days so I can get back in after wash-sale period below 4. I'm willing to wait on the house's dime for a bit
I think you would be safe going back into GILD as most believe it us undervalued against forward earnings. Personally, I think all the talk about regulating the price of Savaldi is just that...all talk. Can you imagine letting the government have the power to set prices of a drug? Where would the line be drawn? Then there is talk about AbbVie's Hep C being an alternative to Gileads at a lower price though consensus is it is not as good. Would anyone really want something for a life threatening illness that is "not as good"? I would think the patient and insurance would want more of a guarantee. Then there is news that GILD is coming out with an 8 week dose. With their pipline and profits, GILD is poised as a juggernaut. Then their is SGEN. Can you believe that pipeine? OPK and ARRY's day will come, but as we discussed late last year, their time is 2015 and beyond. I may pay more to get back in, but I think I'll make more before I do. Always good to discuss things with you Burn.
Good choices ads, I sold my gild, ouch. Still holding this and opk, but like yours better, lol. They claim it is good if they get the drug back, but I really wanted Novartis to run with it. Arry = no sales force, so it will be a mixed blessing, that and though cash is OK short term, not so sure about a drug launch.
Hi Burn. Long time. Just checking in after earnings and am not too surprised. I like all the prospects for ARRY, but like you said, there is a lot of uncertainty and very little clarity. I held on to this for more than a year and rode the ups and downs, but I sold out about a month ago when it was at $4.65. I traded into SGEN pretty heavy at $35.27 close to a 52 week low for them, and started a position in GILD at $89.00. I couldn't be happier with my decision. I'll look to get back into ARRY someday, but not until there is more clarity. As always, I wish you all the best with your investments.
There is a ton of uncertainty regarding Binimetinib, will Novartis return it, finance balance of phase 3 studies, does it mean ALL those phase 2 studies are halted or will get halted. If Novartis does not finance ALL the phase 3, how will Arry finish funding? At least one application was to go to the FDA in 2015, so trial is very near complete.
Arry could give no definitive answers. Only a bunch of maybes, Maybe Novartis will fund all, but maybe not quite all, maybe they give it back, really up to regulators.
One Novartis and one Astra partnered drug COULD go to the FDA in next 12 months, be on the market by 2016. Currently the Novartis drug though not quite in limbo, it is close.
So it is really a matter of time, and these studies certainly take LONG enough. The problem with that is each day new technologies are coming on line clouding the scenery.
This one needs about one more year for things to clear up. Until then, happy trading.
I for one was hoping for clarity, um, maybe to much to ask for.
Has he earned his pay checks over the last year while the stock keeps going lower and lower and lower? Only a fool would say yes!